Levonorgestrel-releasing intrauterine system for the treatment of endometriosis: Biological and clinical evidence

Women's Health

Volumn 3, Issue 2, 2007, Pages 207-214

  Viganò, Paola ^a   Somigliana, Edgardo ^a   Vercellini, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Dysmenorrhea; Dyspareunia; Endometriosis; Levonorgestrel releasing intrauterine system; Pelvic pain; Progestins

Indexed keywords

GESTAGEN; GONADORELIN DERIVATIVE; LEVONORGESTREL;

AMENORRHEA; APOPTOSIS; CELL PROLIFERATION; CLINICAL TRIAL; DECIDUA; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PERITONEAL FLUID LEVEL; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG TISSUE LEVEL; DYSMENORRHEA; DYSPAREUNIA; ENDOMETRIOSIS; ENDOMETRIUM ATROPHY; ENDOMETRIUM CELL; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LAPAROSCOPIC SURGERY; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MENSTRUATION; OLIGOMENORRHEA; PATIENT SATISFACTION; PELVIS PAIN SYNDROME; POSTOPERATIVE CARE; QUALITY OF LIFE; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SPOTTING; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; UTERUS BLOOD FLOW; UTERUS SURGERY;

EID: 33947693200     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.3.2.207     Document Type: Review

References (42)

1. Vercellini P, Fedele L, Pietropaolo G, Frontino G, Somigliana E, Crosignani PG: Progestogens for endometriosis: forward to the past. Hum. Reprod. Update 9, 387-396 (2003).
2. Vercellini P, Cortesi I, Crosignani PG: Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil. Steril. 68, 393-401 (1997).
3. Nilssön CG, Lähteenmäki P, Luukkäinen T: Sustained intrauterine release of levonorgestrel over five years. Fertil. Steril. 45, 805-807 (1986).
4. Fedele L, Bianchi S, Raffaelli R, Portuese A, Dorta M: Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil. Steril. 68, 426-429 (1997).
5. Silverberg SG, Häukkamaa M, Arko H, Nilssön CG, Luukkainen T: Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int. J. Gynecol. Pathol. 5, 235-241 (1986).
6. Shulman LP, Nelson AL, Darney PD: Recent developments in hormone delivery system. Am. J. Obstet. Gynecol. 190, S39-S48 (2004).
7. Xiao BL, Zhou LY, Zhang XL et al.: Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 41. 353-362 (1990).
8. Luukkäinen T: The levonorgestrel intrauterine system: therapeutic aspects. Steroids 65, 699-702 (2000).
9. Barbosa I, Bakos O, Olsson SE, Odlind V, Johansson ED: Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 42, 51-66 (1990).
10. Nilssön CG, Lähteenmäki P, Luukkäinen T: Patterns of ovulations and bleeding with a low levonorgestrel-releasing intrauterine device. Contraception 21, 155-164 (1980).
11. Nilsöon CG, Lähteenmäki P, Luukkäinen T: Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil. Steril. 41, 52-55 (1984).
12. Bahamondes L, Hidalgo M, Petta CA, Diaz J, Espejo-Arce X, Monteiro-Dantas C: Enlarged ovarian follicles in users of a levonorgestrel-releasing intrauterine system and contraceptive implant. J. Reprod. Med. 48. 637-640 (2003).
13. Casslen B, Nordengren J, Gustavsson B. Nilbert M, Lund LR: Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor. J. Clin. Endocrinol. Metab. 80, 2776-2784 (1995).
14. Casslen B, Urano S, Ny T: Progesterone regulation of plasminogen activator inhibitor 1 (PAI- 1) antigen and mRNA levels in human endometrial stronial cells. Thromb. Res. 66, 75-87 (1992).
15. Rogers PA, Au CL, Affandi B: Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel. Hum. Reprod. 8, 1396-1404 (1993).
16. Silverberg SG, Haukkämaa M, Arko H, Nilssön CG, Luukkäinen T: Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int. J. Gynecol. Pathol. 5, 235-241 (1986).
17. Järvelä I, Tekay A, Jöuppilä P: The effect of a levonorgestrel intrauterine system on uterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women. Hum. Reprod. 13, 3379-3383 (1998).
18. Päkärinen P, Luukkäinen T, Läine H, Lähteenmäki P: The effect of local intrauterine levonorgestrel administration on endometrial thickness and uterine blood circulation. Hum. Reprod. 10, 2390-2394 (1995).
19. Zalel Y, Shulman A, Lidor A, Achiron R, Mashiach S, Gamzu R: The local progestational effect of the levonorgestrel-releasing intrauterine system; a sonographic and Doppler flow study. Hum. Reprod. 17, 2878-2880 (2002).
20. Lockhat FB, Emembolu JO, Korje JC: The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease. Hum. Reprod. 19, 179-184 (2004).
21. Higham JM, O'Brien PM, Shaw RW: Assessment of menstrual blood loss using a pictorial chart. Br. J. Obstet. Gynaecol. 97, 734-739 (1990).
22. American Fertility Society: Revised American Fertility Society classification of endometriosis. Fertil. Steril. 43, 351-352 (1985).
23. Lockhat FB, Emembolu JO, Konje JC: The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum. Reprod. 20, 789-793 (2005).
24. Petta CA, Ferriani RA, Abrao MS et al.: Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum. Reprod. 20, 1993-1998 (2005).
25. Duputy HJ: The Psychological General Well-Being (PGWB) index. In: Amessment of Quality ofLffe in Clinical Trials. Wenger NK, Mattson ME, Furberg CD, Elinson J (Eds). Le Jacq Publishing, NY, USA, 170-183, 353-356 (1984).
26. Fedele L, Bianchi S, Zanconato G, Portuese A, Raffaelli R: Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil. Steill. 75, 485-488 (2001).
27. Vercellini F, Aimi G, Panazza S, De Giorgi O, Pesole A, Crosignani PG: A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil. Steril. 72, 505-508 (1999).
28. Vercellini P, Frontino, G, De Giorgi O, Aimi G, Zaina B, Crosignani PG: Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil. Steril. 80, 305-309 (2003).
29. Sälmi A, Päkärinen P, Peltola AM, Rutänen EM: The effect of intrauterine levonorgestrel use on the expression of C-Jun, oestrogen receptors, progesterone receptors and Ki-67 in human endometrium. Mol. Hum. Reprod. 4, 1110-1115 (1998).
30. Maruo T, Laoag-Fernandez JB, Pakarinen P, Murakosbi H, Spitz IM, Johansson E: Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. Hum. Reprod. 16, 2103-2108 (2001).
31. Jones RL, Critchley HO: Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum. Reprod. 15(Suppl. 3), 162-172 (2000).
32. Critchley HO, Wang H, Jones RL et al.: Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery. Hum. Reprod. 13, 1218-1224 (1998).
33. Hurskäinen R, Säimi A, Päavonen J, Teperi J. Ruäanen E: Expression of sex steroid receptors and Ki-67 in the endometria of menorrhagic women: effects of intrauterine levonorgestrel. Mol. Hum. Reprod. 6, 1013-1018 (2000).
34. Roopa BA, Loganath A, Singh K: The effect of a levonorgestrel-releasing intrauterine system on angiogenic growth factors in the endometrium. Hum. Reprod. 18, 1809-1819 (2003).
35. Zalel Y, Gamzu R, Shulman A, Achiron R, Schiff G, Lidor A: The progestative effect of the levonorgestrel-releasing intrauterine system - when does it manifest? Contraception 67, 473-476 (2003).
36. Vercellini P, De Giorgi O, Aimi G, Panazza S, Uglietti A, Crosignani PG: Menstrual characteristics in women with and without endometriosis. Obstet. Gynecol. 90, 264-268 (1997).
37. Suhonen S, Haukkamäa M, Jäkobsson T, Rauramo I: Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nuiliparous women: a comparative study. Contiaception 69, 407-412 (2004).
38. Jain S, Dalton ME: Chocolate cysts from ovarian follicles. Fertil. Steril. 72, 852-856 (1999).
39. Nilssön CG, Lähteenmäki P, Luukkäinen T: Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel IUD. Contraception 21, 225-233 (1980).
40. Nilssön CG, Lähteenmäki P, Robertson DN, Luukkäinen T: Plasma concentrations of levonorgestrel as a function of the release rate of levonorgestrel from medicated intrauterine devices. Acta Endocrinol. 93, 380-384 (1980).
41. Lockhat FB, Emembolu JE, Konje JC: Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel. Fertil. Steril. 83, 398-404 (2005).
42. Nilsöon CG, Häukkamaa M, Vieröla H, Luukkäinen T: Tissue concentration of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin. Endocrinol. 17, 529-536 (1982).